Efficacy and safety of Yukmijihwang-tang in patients with type 2 diabetes who have microalbuminuria- a pilot study
- Conditions
- Endocrine, nutritional and metabolic disease
- Registration Number
- KCT0001853
- Lead Sponsor
- Daegu Catholic University Medical Center
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 30
Patients are eligible to be included in the study only if they meet all of the following criteria;
? Subject who is more than18 years of age and younger than 80 years of age has been diagnosed with type 2 diabetes mellitus.
? Subject who have micromabumiuria (30-300mg/day)
? Subject agrees to participate in this study and writes Informed consent.
Patient will be excluded from the study if they meet any of the following criteria;
?Subject has a Hb A1c value more than 9%, hyperglycemia or symptom due to poorly controlled glucosefor at least 3 months, and should be required more intense medications based on the investigator's judgement.
?Subjects is currently receving or changing Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
?Subject is participating in another clinical study.
?Subject has a history of an active malignancy, Chronic kidney disease stage 4 or more, serious conditions such as hepatic or heart disease
?Subject is the female of childbearing potential who are pregnant, breast-feeding, or not using adequate contraceptive methods
?Subject currently has a history of severe physical activity, fever, elevation of blood pressure, or high protein diet.
?Subject has episodes of nausea, vomiting, or acute gastrointestinal symptom within the 2 weeks before
Study & Design
- Study Type
- Interventional Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Microalbuminuria
- Secondary Outcome Measures
Name Time Method cystatin C;N-acetyl-b-D-glucosaminidase;urinary neutrophil gelatinase-associated ipocalin; HbA1c;fructosamin;fasting plasma glucose